Development of Rna Vaccines for leishmaniasis and comparison with vaccines based on recombinant antigens

Authors

• Gabriela de Asis Burle-Caldas, UFMG/CTVacinas, BrazilFollow
• Isabela Vieira da Costa, Federal University of Minas Gerais (UFMG)/Center of Vaccine Technology (CTVacinas)
• Renata Salgado Fernandes, Federal University of Minas Gerais (UFMG)/Center of Vaccine Technology (CTVacinas)
• Bianca de Oliveira, Federal University of Minas Gerais (UFMG)/Center of Vaccine Technology (CTVacinas)
• Ana Flávia Bráz, Federal University of Minas Gerais (UFMG)/Center of Vaccine Technology (CTVacinas)
• Diego dos Santos Ferreira, Federal University of Minas Gerais (UFMG)/ School of Pharmaceutical Sciences
• Frederico Crepaldi Nacimento, Federal University of Minas Gerais (UFMG)/ School of Pharmaceutical Sciences
• Ricardo Tostes Gazzinelli, Federal University of Minas Gerais (UFMG)/Center of Vaccine Technology (CTVacinas)
• Ana Paula Fernandes, Federal University of Minas Gerais (UFMG)/Center of Vaccine Technology (CTVacinas)
• Santuza Maria Ribeiro Teixeira, Federal University of Minas Gerais (UFMG)/Cente

Conference Dates

May 19 - 24, 2024

Abstract

Please click Additional Files below to see the full abstract.

Recommended Citation

Gabriela de Asis Burle-Caldas, Isabela Vieira da Costa, Renata Salgado Fernandes, Bianca de Oliveira, Ana Flávia Bráz, Diego dos Santos Ferreira, Frederico Crepaldi Nacimento, Ricardo Tostes Gazzinelli, Ana Paula Fernandes, and Santuza Maria Ribeiro Teixeira, "Development of Rna Vaccines for leishmaniasis and comparison with vaccines based on recombinant antigens" in "Vaccine Technology IX", Linda Lua, The University of Queensland, Australia; Charles Lutsch, Sanofi-Vaccines, France; Francesc Gòdia, Universitat Autònoma de Barcelona (UAB), Spain; Tara Tagmyer, CMC Leader, USA Eds, ECI Symposium Series, (2024). https://dc.engconfintl.org/vaccine_ix/46